CollaGenex OK'D on Oral Rosacea Drug
Posted on: Tuesday, 30 May 2006, 12:00 CDT
CollaGenex said Tuesday it has received U.S. approval to market Oracea, which the company said is the first approved oral rosacea drug.
The company said the Food and Drug Administration has cleared for market Oracea to treat adults with the inflammatory lesions, including papules and pustules, caused by the skin condition.
CollaGenex said it would roll out the new dermatologic drug in July.
Oracea is the first FDA-approved, orally-administered, systemically-delivered drug to treat rosacea, the company said in a statement.
Rosacea affects about 14 million adults in the United States, CollaGenex said.
Oracea is the first of a series of dermatology products we have in development, and we are very pleased that our NDA was approved by the FDA within 10 months of submission, said Colin Stewart, CollaGenex's president and chief executive officer.
Source: United Press International
Related Articles
- Drug Makers Fail to Begin 71% of Promised Studies of Drugs Already Approved for the Market
- Merck's Anti-Nausea Drug Emend Approved
- FDA Says Impax Parkinson's Drug Not Approvable
- Cancer Drug Rituxan Approved As Arthritis Treatment
- CollaGenex Seeks UK Approval for Oracea
- Insmed Drug Wins Approval; Growth-Hormone Medicine Could Help the Henrico Firm Expand Its Product Line
- Several AIDS Drugs Tentatively Approved
- Torchmark Corporation Subsidiary United American Receives Medicare Part D Prescription Drug Plans Approval From CMS
- Takeda's Diabetes Drug Gets U.S. Approval
- Mich. Will Require ADD Drug Pre-Approval
 |
 |
User Comments (0)
RSS Feeds